JAK1 and congenital rubella syndrome: Other JAK inhibitors such as itacitinib (JAK1 specific) have been used to prevent GVHD when used as prophylaxis for haploidentical allogeneic stem cell transplant (44), for CRS mitigation induced by CAR T therapy (45) and for multiple other inflammatory disorders (17).